Platelet Inhibition with Ticagrelor versus Clopidogrel in Diabetic Patients after Percutaneous Coronary Intervention for Chronic Coronary Syndromes.

Thrombosis and Haemostasis
Zhenyu LiuShuyang Zhang

Abstract

 Clopidogrel is currently the only P2Y12 inhibitor with class I recommendation in patients after percutaneous coronary intervention (PCI) for chronic coronary syndromes (CCS). Diabetic patients have reduced therapeutic response to clopidogrel.  This study assessed the antiplatelet effect of ticagrelor versus clopidogrel in diabetic patients after recent PCI for CCS.  Eligible patients were randomly assigned to receive ticagrelor 90 mg twice daily or clopidogrel 75 mg once daily, in addition to aspirin 100 mg once daily for 15 days. P2Y12 reaction unit (PRU) and percent inhibition were measured by VerifyNow P2Y12 assay. High on-treatment platelet reactivity (HOPR) was defined as PRU > 208. Bleeding was assessed by the Platelet Inhibition and Patient Outcomes criteria. Cardiac ischemic events were evaluated as adverse events.  The baseline characteristics of the patients (n = 39) were well balanced between the two groups. Both before and 2 to 4 hours after the final study dose on day 15, PRU was lower (41.3 ± 35.8 vs. 192.6 ± 49.5, p < 0.001; 36.6 ± 25.8 vs. 187.6 ± 70.9, p < 0.001), percent inhibition was higher (83.0% [70.5%, 96.0%] vs. 16.0% [0%, 25.0%], p < 0.001; 85.0% [76.0%, 96.5%] vs. 25.0% [0%, 39.0%], p < 0.001), and HO...Continue Reading

References

Sep 19, 1998·Journal of the American College of Cardiology·A AbizaidM B Leon
Dec 19, 1998·Journal of the American College of Cardiology·S EleziA Schömig
Jul 27, 2001·Diabetes Care·A I VinikG L Pittenger
Jul 2, 2003·Diabetes Care·John A Colwell, Richard W Nesto
Aug 12, 2004·Journal of Thrombosis and Haemostasis : JTH·P FerroniG Davì
Jul 18, 2006·Journal of the American College of Cardiology·Dominick J AngiolilloAntonio Fernandez-Ortiz
Nov 18, 2006·Thrombosis Research·Paul A Gurbel, Udaya S Tantry
Apr 10, 2007·Journal of the American College of Cardiology·Dominick J AngiolilloMarco A Costa
Oct 16, 2007·Journal of the American College of Cardiology·Dominick J AngiolilloAntonio Fernandez-Ortiz
Mar 7, 2009·Journal of the American College of Cardiology·Dirk SibbingNicolas von Beckerath
Mar 10, 2009·Fundamental & Clinical Pharmacology·Steen Husted
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén
Feb 25, 2010·JAMA : the Journal of the American Medical Association·Nicoline J BreetJurriën M ten Berg
Oct 13, 2011·Journal of Neurointerventional Surgery·UNKNOWN American College of Cardiology Foundation/American Heart Association Task ForceAllen J Taylor
Sep 27, 2013·European Heart Journal·Dániel AradiUNKNOWN Working Group on Thrombosis of the European Society of Cardiology
Oct 1, 2013·Journal of the American College of Cardiology·Udaya S TantryUNKNOWN Working Group on On-Treatment Platelet Reactivity
Mar 17, 2015·The New England Journal of Medicine·Marc P BonacaUNKNOWN PEGASUS-TIMI 54 Steering Committee and Investigators
Oct 7, 2015·Cardiovascular Revascularization Medicine : Including Molecular Interventions·Leonardo C ClavijoMatthew J Price
Aug 31, 2018·European Heart Journal·Franz-Josef NeumannUNKNOWN ESC Scientific Document Group
Sep 3, 2019·The New England Journal of Medicine·P Gabriel StegUNKNOWN THEMIS Steering Committee and Investigators
Sep 11, 2019·European Heart Journal·Juhani KnuutiUNKNOWN ESC Scientific Document Group
Mar 7, 2020·JACC. Cardiovascular Interventions·Dominick J AngiolilloMatthew J Price

❮ Previous
Next ❯

Citations

Aug 20, 2021·The Journal of Clinical Endocrinology and Metabolism·Ying-Ying ZhengXiang Xie

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.